NorthWest Biotherapeutics Inc (NWBO)

[dstock07734]

Gary,

Would you agree DCVax-L is revolutionary? If it is revolutionary, any BP who owns DCVax-L could be the target for market monopoly investigation.
Take a look at all the BPs. Each one of them has acquisitions on ADCs and t-cell engagers. They are all for precision medicines. Here is what Amgen put on its webpage. Amgen claimed that now they have the knowledge and tools to identify the targets that precision medicines can carry. I found nearly all the BPs were hiring people to do target identification job. I suspect it has something to do with DCVax-L.

Scientists and doctors now have the knowledge and tools to identify certain genetic mutations, or biomarkers, in some cancer cells that can be treated with targeted therapies. Yet, even with the availability of these precision medicines, the one-size-fits-all approach of non-targeted therapies remains the standard of care for a majority of patients.

https://www.amgen.com/stories/2019/11/biomarker-testing-in-personalized-cancer-medicine